Balchem Q2 2026: Sales Jump 11% to $284M, EPS $1.39; Credit Facility Expanded to $650M
BCPC sits 20% above its 52-week low of $139.17.
Summary
Balchem posted record Q2 results with sales of $284M (+11% YoY) and EPS of $1.39, beating expectations. The credit facility was upsized to $650M, extending runway for strategic initiatives.
Key Events · Earnings and Guidance · BCPC
-
Q2 Sales and Earnings Beat
Net sales rose 11% to $284M, with all three segments growing. Diluted EPS was $1.39, up from $1.17 a year ago, driven by higher volumes and favorable mix.
-
Credit Facility Upsized to $650M
Amendment No. 1 increased the revolving commitment from $550M to $650M and extended maturity to July 2031, enhancing liquidity for growth and acquisitions.
-
Share Repurchases Continue
The company repurchased $44.5M of common stock in H1 2026 under its December 2025 program, with 3.66M shares remaining authorized.
-
Working Capital Build
Inventories increased to $161.6M from $131.4M at year-end 2025, reflecting higher raw material and finished goods levels to support demand.
Analysis · BCPC · Industrial Applications And Services
A broad-based beat marked Balchem's Q2, with sales climbing 11% to $284M and adjusted EPS of $1.49 topping consensus. All three segments contributed to the growth, led by a 15% surge in Animal Nutrition & Health. The company also amended its credit agreement, boosting the revolver to $650M and pushing maturity out to 2031, which provides ample liquidity for growth and acquisitions. Share repurchases continued, with $44.5M spent in H1. The strong quarter and enhanced financial flexibility reinforce the company's solid operating momentum.
At the time of this filing, BCPC was trading at $167.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $139.17 to $183.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.